[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

September 2019 - April 2015

Decade

Year

Issue

August 2016, Vol 2, No. 8, Pages 973-1103

Original Investigation

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1014-1022. doi:10.1001/jamaoncol.2016.0173

This study investigates the sensitivity, specificity, test turnaround time, and robustness of droplet digital polymerase chain reaction–based plasma genotyping for the rapid detection of targetable genomic alterations in patients with advanced non–small-cell lung cancer.

Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors

Abstract Full Text
open access
JAMA Oncol. 2016;2(8):1023-1029. doi:10.1001/jamaoncol.2016.0386

This study evaluates cases of encapsulated follicular variant of papillary thyroid carcinoma to establish consensus diagnostic criteria and develop new nomenclature.

Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1030-1037. doi:10.1001/jamaoncol.2016.1726

This randomized clinical trial evaluates whether angiotensin II–antagonist treatment with candesartan can prevent or ameliorate trastuzumab-related cardiotoxic effects and what biomarkers might be used to identify patients at increased risk of such toxic effects.

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1040-1047. doi:10.1001/jamaoncol.2016.0339

This secondary analysis of the HERA trial examines how HER2 amplification and estrogen receptor expression levels influence response to trastuzumab following adjuvant chemotherapy in patients with early-stage HER2-positive breast cancers.

Prolonged Nightly Fasting and Breast Cancer Prognosis

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1049-1055. doi:10.1001/jamaoncol.2016.0164

This study investigates whether duration of nightly fasting is associated with breast cancer recurrence and mortality among patients with early-stage breast cancer and, if so, whether it was associated with risk factors for poor outcomes, including glucoregulation, chronic inflammation, obesity, and sleep.

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor–Refractory Metastatic Melanoma: A Phase 2 Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1056-1064. doi:10.1001/jamaoncol.2016.0509

This phase 2 clinical trial evaluates the overall response rate and progression-free survival and overall survival associated with dabrafenib-trametinib combination therapy in patients with metastatic melanoma that progressed on BRAF inhibitor monotherapy.

Brief Report

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1065-1069. doi:10.1001/jamaoncol.2016.1396

This analysis analyzes a cohort of 39 pregnant women with Hodgkin or non-Hodgkin lymphoma diagnosed during pregnancy to determine therapies for successful maternal and fetal outcomes.

Racial/Ethnic Disparities in Genomic Sequencing

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1070-1074. doi:10.1001/jamaoncol.2016.1854

This study looks at the association of ethnic diversity and the pathogenesis of cancer, and the generalizability of findings from The Cancer Genome Atlas to racial minorities.

Research Letter

Associations Between Parkinson Disease and Cancer in US Asian Americans

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1093-1094. doi:10.1001/jamaoncol.2016.0729

This secondary analysis of Surveillance, Epidemiology, and End Results and Medicare data restricted to Asian Americans examines the associations between Parkinson disease and cancer in population most likely to be ethnically similar to a previously studied Taiwanese population.

Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1094-1096. doi:10.1001/jamaoncol.2016.1056

This cohort study evaluates associations between ERCC2 mutations and survival among patients with muscle-invasive urothelial bladder carcinoma treated with chemotherapy.

Review

Postoperative Radiotherapy After Breast-Conserving Surgery for Early-Stage Breast Cancer: A Review

Abstract Full Text
JAMA Oncol. 2016;2(8):1075-1082. doi:10.1001/jamaoncol.2015.5805

This review describes the effect of postoperative radiotherapy on recurrence and survival in women with breast cancer who have undergone breast-conserving surgery.

Management of Ductal Carcinoma In Situ of the Breast: A Review

Abstract Full Text
JAMA Oncol. 2016;2(8):1083-1088. doi:10.1001/jamaoncol.2016.0525

This narrative review summarizes standard of care treatment options for ductal carcinoma in situ.

JAMA Oncology Clinical Evidence Synopsis

Different Platelet Count Thresholds to Guide Use of Prophylactic Platelet Transfusions for Patients With Hematological Disorders After Myelosuppressive Chemotherapy or Stem Cell Transplantation

Abstract Full Text
JAMA Oncol. 2016;2(8):1091-1092. doi:10.1001/jamaoncol.2016.2466

This Clinical Evidence synopsis summarizes an updated Cochrane review of trials comparing platelet count thresholds for initiating platelet transfusions to prevent bleeding after myelosuppressive chemotherapy or stem cell transplantation.

Viewpoint

Treatment of Regional Lymph Nodes in Breast Cancer—Evidence in Favor of Radiation Therapy

Abstract Full Text
JAMA Oncol. 2016;2(8):989-990. doi:10.1001/jamaoncol.2016.0183

This Viewpoint argues that all women with breast cancer and positive regional lymph nodes should receive comprehensive nodal irradiation.

Treatment of Regional Lymph Nodes in Breast Cancer—Not Recommended for All Patients With 1 to 3 Positive Auxiliary Nodes

Abstract Full Text
JAMA Oncol. 2016;2(8):991-992. doi:10.1001/jamaoncol.2016.0222

This Viewpoint argues that evidence does not yet support use of comprehensive nodal irradiation for women with breast cancer and 1 to 3 positive regional lymph nodes.

Internal Mammary Node Radiation in Light of the EORTC 22922 and MA.20 Trials—What Have We Really Learned?

Abstract Full Text
JAMA Oncol. 2016;2(8):992-993. doi:10.1001/jamaoncol.2015.5810

This Viewpoint examines results from the MA.20 and EORTC 22922 trials and what they mean for the treatment of patients with internal mammary node involvement using radiotherapy.

The Potential Role of Patient Navigation in Low- and Middle-Income Countries for Patients With Cancer

Abstract Full Text
JAMA Oncol. 2016;2(8):994-995. doi:10.1001/jamaoncol.2016.0766

This Viewpoint assesses the potential role of patient navigation programs for patients with cancer in low- and middle-income countries.

From the JAMA Network

Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome

Abstract Full Text
JAMA Oncol. 2016;2(8):1089-1090. doi:10.1001/jamaoncol.2016.0614

This commentary on an article recently published in JAMA discusses long-term results of luteinizing hormone–releasing hormone analogue–induced ovarian suppression during breast cancer chemotherapy.

Editorial

The Case for Skin Cancer Screening With Total-Body Skin Examinations

Abstract Full Text
JAMA Oncol. 2016;2(8):999-1001. doi:10.1001/jamaoncol.2016.2440

This Editorial discusses the US Preventive Services Task Force recommendation statement on screening for skin cancer and argues in favor of total-body skin examinations.

Colorectal Cancer Screening: Which Test Is Best?

Abstract Full Text
JAMA Oncol. 2016;2(8):1001-1003. doi:10.1001/jamaoncol.2016.2494

This editorial reviews the the US Preventive Services Task Force June 2016 recommendation statement on colorectal cancer screening.

Clinical Application of Liquid Biopsies

Abstract Full Text
JAMA Oncol. 2016;2(8):1003-1005. doi:10.1001/jamaoncol.2016.0240

Noninvasive Encapsulated Follicular Variant of Papillary Thyroid “Cancer” (or Not): Time for a Name Change

Abstract Full Text
JAMA Oncol. 2016;2(8):1005-1006. doi:10.1001/jamaoncol.2016.0714
Invited Commentary

Cardiac Protection in HER2-Targeted Treatment: How Should We Measure New Strategies?

Abstract Full Text
JAMA Oncol. 2016;2(8):1037-1039. doi:10.1001/jamaoncol.2016.0283

Adjuvant Trastuzumab Benefit in Patients Diagnosed With Triple-Positive Breast Cancer

Abstract Full Text
JAMA Oncol. 2016;2(8):1047-1048. doi:10.1001/jamaoncol.2016.0446
JAMA Oncology Patient Page

Jaundice (Hyperbilirubinemia) in Cancer

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1103. doi:10.1001/jamaoncol.2016.1236
Cancer Care Chronicles

Replacing Urban Myths About Cancer With Community Wisdom: Putting a Finger on Cancer Disparities

Abstract Full Text
JAMA Oncol. 2016;2(8):996-998. doi:10.1001/jamaoncol.2015.6566
Comment & Response

Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations—Reply

Abstract Full Text
JAMA Oncol. 2016;2(8):1096-1097. doi:10.1001/jamaoncol.2016.1963

Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations

Abstract Full Text
JAMA Oncol. 2016;2(8):1096. doi:10.1001/jamaoncol.2016.2161

Ramifications of New Terminology for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma

Abstract Full Text
JAMA Oncol. 2016;2(8):1097. doi:10.1001/jamaoncol.2016.2208

Ramifications of New Terminology for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma

Abstract Full Text
JAMA Oncol. 2016;2(8):1097-1098. doi:10.1001/jamaoncol.2016.2211

Ramifications of New Terminology for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma—Reply

Abstract Full Text
JAMA Oncol. 2016;2(8):1098-1099. doi:10.1001/jamaoncol.2016.2205
Correction

Error in Funding Statement

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1099. doi:10.1001/jamaoncol.2016.1752

Incorrect Figure Key

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):1099. doi:10.1001/jamaoncol.2016.3365
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):978. doi:10.1001/jamaoncol.2015.3527
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2016;2(8):973. doi:10.1001/jamaoncol.2015.3526
×